Safety and Effectiveness of Intravitreal Dexamethasone Implant (Ozurdex®) for the Treatment of Refractory Cystoid Macular Oedema (CMO) in Galway University Hospital

Bobby Tang1, *, Casserene E. Shen Yeow2, Fiona Harney2, Deirdre Townley2
1 Royal Victoria Eye & Ear Hospital, Adelaide Road, Dublin, Ireland
2 University College Hospital Galway, Newcastle Road, Galway, Ireland

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 290
Abstract HTML Views: 129
PDF Downloads: 234
ePub Downloads: 108
Total Views/Downloads: 761
Unique Statistics:

Full-Text HTML Views: 179
Abstract HTML Views: 101
PDF Downloads: 149
ePub Downloads: 86
Total Views/Downloads: 515

Creative Commons License
© 2022 Tang et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Royal Victoria Eye & Ear Hospital, Adelaide Road, Dublin; E-mails:,



The aim of this study is to assess the real-life effectiveness and safety of intravitreal Ozurdex in an Irish setting.


Ozurdex is an intravitreal dexamethasone implant that is used for the treatment of macular oedema secondary to retinal vein occlusion and diabetic macular oedema.


This was a retrospective observational study of adult patients in University Hospital Galway who received an intravitreal dexamethasone implant (Ozurdex) for the treatment of cystoid macular oedema secondary to diabetic eye disease or retinal vein occlusion. The main outcome was the mean change in best-corrected visual acuity 3-6 months after the treatment.

Results and Discussion:

36 patients were included in the study. Overall, there was a 1.66 mean letter gain (SD 11.8) 3-6 months post-treatment. The proportion of patients who gained >10 letters was 15.6%. The mean reduction in CST was 110.6um (SD 255.7), and in the linear regression analysis, no variables were found to be significantly associated with a change in visual acuity. In terms of adverse events, 14.3% of patients had significant cataract progression and 20.6% of patients had a significant rise in IOP following intravitreal Ozurdex implant.


Intravitreal Ozurdex was found to be safe and effective, supporting it as an appropriate second-line treatment in patients with refractory macular oedema secondary to diabetic eye disease and retinal vein occlusion. Further studies should be carried out to evaluate the possible predictors of visual acuity outcome.

Keywords: Diabetic, Eye disease, Retinal vein occlusion, Cystoid macular oedema, Diabetic macular oedema, Treatment.